Skip to main content

Table 1 Cytogenetic classification and response to therapy at day 28 after induction therapy for AML patients

From: Lymphoid enhancer-binding factor 1 (LEF-1): a favorable prognostic factor in adult acute myeloid leukemia in Egyptian patients

ParametersPatients
N%
CytogeneticsNormal karyotype1550.0%
t(15;17) (q22;q12)516.7%
t(8,21) (q22;q22)413.3%
inv 16 (p13q22)13.3%
11q23 rearrangement26.7%
Monosomy 713.3%
t(9,22) (q34;q11)13.3%
Trisomy 813.3%
Cytogenetics classification*Poor413.3%
Intermediate1653.3%
Good1033.3%
Response to therapy at day 28Hematological remission930.0 %
Incomplete remission1343.3 %
Died826.7 %
  1. *Patients were classified as good, poor, and intermediate cytogenetic prognostic groups according to cytogenetic analysis where t(8;21) (q22;q22), inv16 (p13;q22), and t(15;17) (q22;q21) were considered as good prognosis, while normal karyotype and trisomy 8 were considered intermediate prognosis, and 11q23 rearrangement, monosomy 7, t(9,22) (q34;q11) were considered poor prognosis by Wang and Bailey [17]